Printer Friendly

SPI PHARMACEUTICALS REINTRODUCES BENOQUIN(R) CREAM

 COSTA MESA, Calif., June 10 /PRNewswire/ -I? Pharmaceuticals Inc. (AMEX: SPI) said today the U.S. Food and Drug Administration (FDA) has granted authorization to reintroduce its prescription depigmenting agent Benoquin(R) (monobenzone) Cream, 20 percent. Benoquin is used for final depigmentation by patients with extensive vitiligo, an incurable skin disease that destroys the body's pigment cells and can leave individuals with patchy spots causing severe cosmetic disfigurement.
 Benoquin, a topical cream, depigments skin not affected by the disease, resulting in a uniform coloration of all skin. The prescription medication has been available in the United States for many years, but production was discontinued in 1990 by SPI pending approval of a change in the source of supply of monobenzone. Over the last 10 months, Benoquin has been provided free of charge to physicians by SPI under an Emergency IND granted by the FDA.
 It is estimated that 1 percent to 2 percent of the entire population is affected to some extent by vitiligo, although most cases are mild. Recently, pop superstar Michael Jackson revealed in a television interview that he suffers from this skin disease.
 The company said it is notifying dermatologists nationwide of the availability of Benoquin. Benoquin is one of a complete line of safe, effective pharmaceuticals manufactured and marketed by SPI to treat pigmentation disorders and is part of a broad range of dermatological products produced by SPI.
 SPI Pharmaceuticals Inc., headquartered in Costa Mesa, manufactures, markets and distributes 600 prescription and non- prescription pharmaceuticals in more than 60 countries.
 -0- 6/10/93
 /CONTACT: Paul Knopick of SPI Pharmaceuticals, 714-545-0100, ext. 2465/
 (SPI)


CO: SPI Pharmaceuticals Inc. ST: California IN: MTC SU: PDT

JB-LS -- LA033 -- 0881 06/10/93 18:33 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 10, 1993
Words:287
Previous Article:BOEING 777 ON TARGET TO FLY IN ONE YEAR
Next Article:MUSICLAND'S NOTE OFFERING DECLARED EFFECTIVE NET PROCEEDS OF SALE WILL BE $107.2 MILLION
Topics:


Related Articles
RUSSIA AUTHORIZES VIRAZOLE FOR TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS
SPI PHARMACEUTICALS RECEIVES LICENSE FROM UNITED NATIONS TO SHIP MATERIALS TO YUGOSLAVIA
SPI PHARMACEUTICALS ANNOUNCES MEXICAN AUTHORIZATION OF VIRAZOLE ANTIVIRAL CREAM FOR HERPES
SPI'S MEXICAN SUBSIDIARY ANNOUNCES $5 MILLION EXPANSION
VIRAZOLE NOW AVAILABLE FOR A NEW USE -- IN MECHANICALLY VENTILATED INFANTS
SPI PHARMACEUTICALS ANNOUNCES SECOND QUARTER DIVIDEND
SPI PHARMACEUTICALS REPORTS FIRST QUARTER SALES AND NET INCOME
SPI PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS; EARNINGS UP 37 PERCENT IN U.S., LATIN AMERICA AND WESTERN EUROPE
SCHERING-PLOUGH LICENSES ORAL ANDROGEN TO SPI PHARMACEUTICALS
VIRAZOLE ANTIVIRAL CREAM AUTHORIZED FOR HERPES LABIALIS IN PANAMA, FOLLOWS MEXICAN INTRODUCTION

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters